Form 4: Neogenomics Executive Reports Stock Transactions
Statement of Changes in Beneficial Ownership
Neogenomics Inc. executive Alicia C. Olivo reported transactions involving stock options, performance stock units, and restricted stock units.
Summary
- Alicia C. Olivo, EVP, GC & Business Development at Neogenomics Inc., filed a Form 4 detailing transactions related to her beneficial ownership of company securities.
- The filing indicates the acquisition of 1,042 shares of Common Stock on May 1, 2026, with ownership directly held.
- A significant portion of the filing details various stock options, performance stock units (PSUs), and restricted stock units (RSUs) granted to Ms. Olivo over several years, with specified vesting schedules and exercise prices.
- These grants include stock options with exercise prices ranging from $9.45 to $48.99, and PSUs and RSUs with no initial exercise price, subject to vesting and performance criteria.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this filing as neutral, as it primarily reports on executive stock transactions and grants without providing new financial performance or strategic information.
Positives
- The filing shows continued equity grants to a key executive, indicating ongoing incentive alignment.
- Ms. Olivo directly holds a substantial number of securities, suggesting a strong personal investment in the company's performance.
Negatives
- The filing does not provide financial performance data or strategic updates, making it difficult to assess the company's overall health from this document alone.
Risks
- The value of stock options and PSUs is subject to the future performance and stock price of Neogenomics Inc.
- Vesting schedules for equity awards mean that a portion of the executive's compensation is contingent on continued service and performance over multiple years.
Future Outlook
The filing primarily details past and current equity grants and transactions, with no explicit forward-looking financial guidance or outlook provided.
Industry Context
StockSavvy.ai notes that Form 4 filings are standard disclosures for executives and directors regarding their equity holdings and transactions. This filing provides insight into the compensation structure and executive's stake in Neogenomics Inc., a company operating in the genomics and diagnostics sector.
Stakeholder Impact
- Shareholders: The filing provides transparency into executive compensation and equity holdings, which can influence perceptions of management alignment and long-term incentives.
- Employees: The structure of executive compensation, including equity grants, can set a precedent for employee incentive programs.
- Management: The filing details Ms. Olivo's equity awards, reflecting her role and compensation within the company.
Next Steps
- Vesting of granted stock options, performance stock units, and restricted stock units according to their respective schedules.
- Potential exercise of vested stock options.
- Achievement of performance criteria for PSUs to determine final vesting amounts.
Key Dates
| Date | Description |
|---|---|
| 05/01/2026 | Earliest transaction date reported and date of acquisition of 1,042 shares of Common Stock. |
| 09/30/2019 | Grant date for a stock option with an exercise price of $19.12. |
| 05/01/2020 | Grant date for a stock option with an exercise price of $27.34. |
| 05/01/2021 | Grant date for a stock option with an exercise price of $48.99. |
| 08/01/2021 | Grant date for a stock option with an exercise price of $46.10. |
| 05/01/2022 | Grant date for a stock option with an exercise price of $9.45. |
| 09/01/2022 | Grant date for a stock option with an exercise price of $10.05. |
| 05/11/2023 | Grant date for a stock option with an exercise price of $19.65, performance stock units, and restricted stock units. |
| 02/23/2024 | Grant date for a stock option with an exercise price of $16.45, performance stock units, and restricted stock units. |
| 02/20/2025 | Reference date for calculating the premium exercise price of a stock option. |
| 02/21/2025 | Grant date for a stock option with an exercise price of $13.05 and restricted stock units. |
| 02/27/2026 | Reference date for calculating the premium exercise price of a stock option. |
| 03/01/2026 | Grant date for a stock option with an exercise price of $10.81 and restricted stock units. |
| 05/05/2026 | Date of signature for the Form 4 filing. |
Keywords
Form 4, Neogenomics Inc., NEO, Stock Options, Restricted Stock Units, Performance Stock Units, Beneficial Ownership, Executive Compensation, SEC Filing
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.